What is Vitreo-Retinal Associates?
Established in 1980, Vitreo-Retinal Associates serves as a cornerstone of specialized ophthalmological care in Central Massachusetts. The practice is led by a team of board-certified surgeons—Dr. Frank J. McCabe, Dr. Brad J. Baker, and Dr. Bryan K. Hong—who focus on the diagnosis and treatment of complex retinal and vitreous conditions. By integrating state-of-the-art surgical techniques with active participation in clinical trials, the firm maintains a high-authority profile in the medical community. Their focus on both pediatric and adult patient populations ensures a comprehensive approach to preserving vision and treating degenerative eye diseases, positioning them as a critical healthcare provider in the region.
The organization operates at the intersection of clinical practice and medical innovation. By prioritizing the latest advancements in retinal disease management, Vitreo-Retinal Associates bridges the gap between traditional patient care and modern therapeutic development. Their reputation for compassionate, high-standard service has allowed them to scale their operations effectively, ensuring that patients receive cutting-edge interventions for delicate nerve tissue conditions.
How much funding has Vitreo-Retinal Associates raised?
Vitreo-Retinal Associates has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Vitreo-Retinal Associates
PPP
Public-Private Partnership
What's next for Vitreo-Retinal Associates?
Following this late-stage capital injection, Vitreo-Retinal Associates is well-positioned to expand its clinical research capabilities and enhance its surgical infrastructure. The strategic allocation of these funds will likely support the integration of advanced diagnostic technologies and the scaling of their clinical trial participation. As the demand for specialized retinal care continues to rise, the firm is expected to leverage this financial backing to optimize patient outcomes and potentially broaden its reach within the Massachusetts healthcare ecosystem. The focus remains on maintaining the highest standards of medical excellence while exploring new methodologies for the prevention and treatment of complex ocular pathologies.
See full Vitreo-Retinal Associates company page
